oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Effects of on outcomes: A systematic review and meta-analysis SOUL trial shows oral semaglutide

As an FDA-approved medication, it belongs to the GLP-1 receptor agonists class, working by mimicking the GLP-1 hormone your body naturally produces after meals

In another study involving more than 96,000 patients initiating GLP-1s, 46% of patients with and 65% without Type 2 diabetes discontinued the drugs within one year

Some of the main factors contributing to Ozempic face include: Rapid Weight Loss and Facial Fat Pad Loss Your face contains distinct fat compartments, called fat pads, that give it structure and a youthful contour

Digestive Issues Some people have reported experiencing mild digestive issues after receiving lipotropic injections